Efficacy and Safety of Vericiguat for Treatment of Heart Failure: A Systematic Review

Shaikh, Taha Gul; Jawed, Shizra; Rahmat, Zainab Syeda; Ahmed, Syed Hassan; Waseem, Summaiyya; Ullah, Irfan; Irfan, Muhammad; Asghar, Muhammad Sohaib

doi:10.1016/j.cpcardiol.2023.101586

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Una RS publicada Shaikh et al 109 en 2023 tuvo como objetivo evaluar el impacto de vericiguat en pacientes con ICFEr. Los autores incluyeron 7 ECAs y los resultados de los metaanálisis indican que el uso de vericiguat se asoció a una disminución en el riesgo de mortalidad de cualquier causa, muerte cardiovascular, y hospitalizaciones por insuficiencia cardiaca 109 . Una RS publicada por Zheng et al en 2018 evaluó el impacto de los modificadores de GCs en pacientes con ICFEr.…”

Section: Revisión De La Literatura Y Análisisunclassified

Guía mexicana de práctica clínica para el diagnóstico y el tratamiento de la insuficiencia cardiaca

Pavía-López,

Magaña-Serrano,

Cigarroa-López

et al. 2024

ACM

View full text Add to dashboard Cite

La insuficiencia cardiaca crónica sigue siendo unas de las principales causas de afectación en el funcionamiento y en la calidad de vida de las personas que la presentan, así como una de las primeras causas de mortalidad en nuestro país y en todo el mundo. México tiene una alta prevalencia de factores de riesgo para desarrollar insuficiencia cardiaca, tales como hipertensión arterial, diabetes y obesidad, lo que hace imprescindible contar con un documento basado en la evidencia que brinde recomendaciones a los profesionales de la salud involucrados en el diagnóstico y el tratamiento de estos pacientes.

show abstract

Section: Revisión De La Literatura Y Análisisunclassified

Guía mexicana de práctica clínica para el diagnóstico y el tratamiento de la insuficiencia cardiaca

Pavía-López,

Magaña-Serrano,

Cigarroa-López

et al. 2024

ACM

View full text Add to dashboard Cite

show abstract

“…The main advantage of this drug is that it avoids the risk of electrolyte imbalance or renal damage [149]. Moreover, vericiguat bypasses the many problems of current therapies, such as the gradual decline in effectiveness, drug dose-dependent tolerance, and off-target effects due to a lack of specificity, thus representing a game changer in the treatment of HF, because it has great potential to reduce the severity of the disease [150].…”

Section: Drug Targeting Of Mitochondrial Ca 2+ and Homeostasismentioning

confidence: 99%

Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies

et al. 2023

View full text Add to dashboard Cite

Mitochondria are key players in energy production, critical activity for the smooth functioning of energy-demanding organs such as the muscles, brain, and heart. Therefore, dysregulation or alterations in mitochondrial bioenergetics primarily perturb these organs. Within the cell, mitochondria are the major site of reactive oxygen species (ROS) production through the activity of different enzymes since it is one of the organelles with the major availability of oxygen. ROS can act as signaling molecules in a number of different pathways by modulating calcium (Ca2+) signaling. Interactions among ROS and calcium signaling can be considered bidirectional, with ROS regulating cellular Ca2+ signaling, whereas Ca2+ signaling is essential for ROS production. In particular, we will discuss how alterations in the crosstalk between ROS and Ca2+ can lead to mitochondrial bioenergetics dysfunctions and the consequent damage to tissues at high energy demand, such as the heart. Changes in Ca2+ can induce mitochondrial alterations associated with reduced ATP production and increased production of ROS. These changes in Ca2+ levels and ROS generation completely paralyze cardiac contractility. Thus, ROS can hinder the excitation–contraction coupling, inducing arrhythmias, hypertrophy, apoptosis, or necrosis of cardiac cells. These interplays in the cardiovascular system are the focus of this review.

show abstract

The Mechanism of Soluble Guanylate Cyclase-Veliciguat for Heart Failure

王

2024

ACM

View full text Add to dashboard Cite

Efficacy and Safety of Vericiguat for Treatment of Heart Failure: A Systematic Review

Cited by 3 publications

References 11 publications

Guía mexicana de práctica clínica para el diagnóstico y el tratamiento de la insuficiencia cardiaca

Guía mexicana de práctica clínica para el diagnóstico y el tratamiento de la insuficiencia cardiaca

Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies

The Mechanism of Soluble Guanylate Cyclase-Veliciguat for Heart Failure

Contact Info

Product

Resources

About